LogicMark, Inc. (LGMK) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.35%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.29% | Research and development expense / revenue. Period ending 2026-06-30. $538.65K ÷ $12.54M × 100 ≈ 4.29% |
| Stock-based compensation / revenue · 12 months | 7.35% | Share-based compensation / revenue. Period ending 2026-06-30. $921.61K ÷ $12.54M × 100 ≈ 7.35% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 538.65K USD | Research and Development Expense |
| Revenue | 12.54M USD | |
| Stock-based compensation | 921.61K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -6.51M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $538.65K | $12.54M | $921.61K | $-6.51M | (m) | 4.29% | 7.35% | (m) | (m) |
| 2026-03-31 | $585.32K | $12.05M | $870.61K | $-7.04M | (m) | 4.86% | 7.23% | (m) | (m) |
| 2025-12-31 | $617.37K | $11.43M | $1.25M | $-7.90M | (m) | 5.40% | 10.90% | (m) | (m) |
| 2025-09-30 | $609.56K | $10.61M | $1.37M | $-8.42M | (m) | 5.75% | 12.90% | (m) | (m) |
| 2025-06-30 | $544.77K | $10.40M | $1.64M | $-8.29M | (m) | 5.24% | 15.79% | (m) | (m) |
| 2025-03-31 | $540.21K | $9.88M | $1.67M | $-8.23M | (m) | 5.47% | 16.93% | (m) | (m) |
| 2024-12-31 | $558.62K | $9.90M | $1.64M | $-7.67M | (m) | 5.64% | 16.52% | (m) | (m) |
| 2024-09-30 | $579.94K | $10.08M | $1.61M | $-14.86M | (m) | 5.75% | 15.94% | (m) | (m) |
| 2024-06-30 | $725.99K | $9.74M | $1.61M | $-15.04M | (m) | 7.45% | 16.55% | (m) | (m) |
| 2024-03-31 | $842.70K | $9.73M | $1.57M | $-15.25M | (m) | 8.66% | 16.09% | (m) | (m) |
| 2023-12-31 | $982.68K | $9.93M | $1.58M | $-15.33M | (m) | 9.90% | 15.89% | (m) | (m) |
| 2023-09-30 | $1.21M | $9.65M | $1.66M | $-8.30M | (m) | 12.50% | 17.19% | (m) | (m) |
| 2023-06-30 | $1.34M | $10.03M | $1.69M | $-8.66M | (m) | 13.34% | 16.89% | (m) | (m) |
| 2023-03-31 | $1.29M | $11.08M | $1.44M | $-7.51M | (m) | 11.67% | 13.03% | (m) | (m) |
| 2022-12-31 | $1.24M | $11.92M | $1.64M | $-6.91M | (m) | 10.42% | 13.80% | (m) | (m) |
| 2022-09-30 | $877.34K | $12.19M | $1.85M | $-10.60M | (m) | 7.20% | 15.15% | (m) | (m) |
| 2022-06-30 | $639.39K | $11.82M | $1.60M | $-8.96M | (m) | 5.41% | 13.54% | (m) | (m) |
| 2022-03-31 | $714.25K | $11.23M | $1.53M | $-8.05M | (m) | 6.36% | 13.59% | (m) | (m) |
| 2021-12-31 | $765.66K | $10.02M | $936.96K | $-7.55M | $1.42M | 7.64% | 9.35% | -5.30× | Reported |
| 2021-09-30 | $1.07M | $10.18M | $328.00K | $-2.49M | $1.93M | 10.52% | 3.22% | -1.29× | Reported |
| 2021-06-30 | $1.13M | $10.44M | $768.00K | $-2.52M | $2.34M | 10.79% | 7.36% | -1.08× | Reported |
| 2021-03-31 | $1.20M | $10.14M | $160.00K | $-2.41M | $2.51M | 11.81% | 1.58% | -0.96× | Reported |
| 2020-12-31 | $1.11M | $11.44M | $160.00K | $-586.08K | $2.25M | 9.69% | 1.40% | -0.26× | Reported |
| 2020-09-30 | $1.00M | $12.89M | $207.51K | $1.19M | $2.33M | 7.78% | 1.61% | 0.51× | Reported |
| 2020-06-30 | $1.10M | $14.70M | $270.04K | $2.44M | $2.91M | 7.48% | 1.84% | 0.84× | Reported |
| 2020-03-31 | $1.19M | $16.70M | $417.77K | $3.11M | $3.04M | 7.13% | 2.50% | 1.02× | Reported |
| 2019-12-31 | $1.21M | $17.14M | $607.71K | $2.58M | $3.02M | 7.05% | 3.55% | 0.85× | Reported |
| 2019-09-30 | $1.20M | $17.15M | $689.88K | $1.52M | $3.00M | 7.01% | 4.02% | 0.51× | Reported |
| 2019-06-30 | $1.05M | $17.07M | $757.04K | $1.02M | $2.45M | 6.14% | 4.43% | 0.42× | Reported |
| 2019-03-31 | $820.54K | $16.96M | $819.82K | $900.66K | $2.80M | 4.84% | 4.83% | 0.32× | Reported |
| 2018-12-31 | $761.72K | $17.12M | $989.68K | $587.49K | $2.97M | 4.45% | 5.78% | 0.20× | Reported |
| 2018-09-30 | $1.68M | $24.71M | $1.93M | $-2.17M | $4.52M | 6.78% | 7.80% | -0.48× | Reported |
| 2018-06-30 | $2.96M | $19.09M | $2.72M | $-6.60M | $6.11M | 15.48% | 14.24% | -1.08× | Reported |
| 2018-03-31 | $2.31M | $21.57M | $2.67M | $-5.45M | $6.79M | 10.73% | 12.38% | -0.80× | Reported |
| 2017-12-31 | $1.67M | $23.32M | $2.49M | $-3.64M | $7.74M | 7.15% | 10.68% | -0.47× | Reported |
| 2017-09-30 | $1.00M | (m) | $1.57M | $-553.31K | $7.19M | (m) | (m) | -0.08× | Reported |
| 2017-06-30 | $406.13K | (m) | $978.54K | $-342.77K | $5.98M | (m) | (m) | -0.06× | Reported |
| 2017-03-31 | $611.81K | (m) | $1.02M | $-3.32M | $4.47M | (m) | (m) | -0.74× | Reported |
| 2016-12-31 | $888.19K | (m) | $1.11M | $-6.71M | $3.28M | (m) | (m) | -2.05× | Reported |
| 2016-09-30 | $1.31M | (m) | $1.32M | $-9.51M | $2.17M | (m) | (m) | -4.37× | Reported |
| 2016-06-30 | $1.96M | (m) | $1.32M | $-11.04M | $1.64M | (m) | (m) | -6.71× | Reported |
| 2016-03-31 | $2.52M | (m) | $1.56M | $-11.20M | $1.76M | (m) | (m) | -6.36× | Reported |
| 2015-12-31 | $2.73M | (m) | $1.51M | $-10.92M | $1.25M | (m) | (m) | -8.74× | Reported |
| 2015-09-30 | $2.78M | (m) | $1.36M | $-9.67M | $760.78K | (m) | (m) | -12.70× | Reported |
| 2015-06-30 | $2.51M | (m) | $1.40M | $-8.21M | $320.80K | (m) | (m) | -25.59× | Reported |
| 2015-03-31 | $1.83M | (m) | $1.02M | $-6.77M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $1.42M | (m) | $792.81K | $-5.25M | $30.74K | (m) | (m) | -170.65× | Reported |
| 2014-09-30 | $973.43K | (m) | $610.07K | $-3.53M | $42.35K | (m) | (m) | -83.29× | Reported |
| 2014-06-30 | $680.73K | (m) | $375.24K | $-2.40M | $57.95K | (m) | (m) | -41.44× | Reported |
| 2014-03-31 | $505.11K | $0.00 | $300.24K | $-1.51M | $62.45K | (m) | (m) | -24.25× | Reported |
| 2013-12-31 | $518.61K | $0.00 | $311.24K | $-1.44M | $35.46K | (m) | (m) | -40.47× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $114.27K | $251.38K | $30.00K | $-193.97K | $247.00 | 45.46% | 11.93% | -785.30× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| ENvue Medical, Inc. (FEED) | United States | $0.011B | |
| Lifeward Ltd. (LFWD) | $0.021B | ||
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |